These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25332171)

  • 21. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis.
    Strang AC; Bisoendial RJ; Kootte RS; Schulte DM; Dallinga-Thie GM; Levels JH; Kok M; Vos K; Tas SW; Tietge UJ; Müller N; Laudes M; Gerlag DM; Stroes ES; Tak PP
    Atherosclerosis; 2013 Jul; 229(1):174-81. PubMed ID: 23746537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
    Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
    Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical effect of tocilizumab on patients with severe active rheumatoid arthritis].
    Xu S; Xie X; Tang M; Chen J; Tian J; Du J; Mao N; Liu Y; Li S; Song M; Gao J; Ling G; Li F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1174-1177. PubMed ID: 29093249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot Study.
    Fechtenbaum M; Lasselin-Boyard P; Salomon S; Jelin G; Millot F; Grados F; Fardellone P; Goëb V
    Pharmacology; 2016; 98(1-2):73-8. PubMed ID: 27115145
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
    Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatigue in rheumatoid arthritis: quantitative findings on the efficacy of tocilizumab and on factors associated with fatigue. The French multicentre prospective PEPS Study.
    Gossec L; Steinberg G; Rouanet S; Combe B
    Clin Exp Rheumatol; 2015; 33(5):664-70. PubMed ID: 26344671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.
    Fortunet C; Pers YM; Lambert J; Godfrin-Valnet M; Constant E; Devilliers H; Gaudin P; Jorgensen C; Prades BP; Wendling D; Maillefert JF
    Rheumatology (Oxford); 2015 Apr; 54(4):672-7. PubMed ID: 25246640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remarkable efficacy of tocilizumab for treating rheumatoid arthritis in patients with high platelet counts.
    Matsuno H
    Mod Rheumatol; 2015 Jan; 25(1):38-42. PubMed ID: 25529071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.
    Bykerk VP; Östör AJ; Alvaro-Gracia J; Pavelka K; Román Ivorra JA; Graninger W; Bensen W; Nurmohamed MT; Krause A; Bernasconi C; Aassi M; Sibilia J
    Clin Rheumatol; 2015 Mar; 34(3):563-71. PubMed ID: 25604316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
    Nishimoto N; Amano K; Hirabayashi Y; Horiuchi T; Ishii T; Iwahashi M; Iwamoto M; Kohsaka H; Kondo M; Matsubara T; Mimura T; Miyahara H; Ohta S; Saeki Y; Saito K; Sano H; Takasugi K; Takeuchi T; Tohma S; Tsuru T; Ueki Y; Yamana J; Hashimoto J; Matsutani T; Murakami M; Takagi N
    Mod Rheumatol; 2014 Jan; 24(1):26-32. PubMed ID: 24261755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
    Karpouzas GA; Ormseth SR; van Riel PLCM; Gonzalez-Gay MA; Corrales A; Rantapää-Dahlqvist S; Sfikakis PP; Dessein P; Tsang L; Hitchon C; El-Gabalawy H; Pascual-Ramos V; Contreras-Yáñez I; Colunga-Pedraza IJ; Galarza-Delgado DA; Azpiri-Lopez JR; Semb AG; Misra DP; Hauge EM; Kitas G
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39043615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
    Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
    Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.
    Kume K; Amano K; Yamada S; Hatta K; Kuwaba N; Ohta H
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1477-81. PubMed ID: 21702090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.
    Bastida C; Soy D; Ruiz-Esquide V; Sanmartí R; Huitema ADR
    Br J Clin Pharmacol; 2019 Aug; 85(8):1710-1718. PubMed ID: 30958574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.